Comparative Bioavailability study with two chlorpropamide tablet formulations in healthy volunteers

Objective. The aim of this study was the assessment of the bioequivalence of two formulations (250 mg tablet) of chlorpropamide (CAS 94-20-2) in 36 healthy volunteers of both sexes. Methods: The study was conducted using an open, randomized, two-period crossover design with a 3-week washout interval. Plasma samples were obtained over a 72-h period. Plasma chlorpropamide concentrations were analyzed by liquid chromatography coupled to tandem mass spectrometry (LC-MS-MS) with positive ion electrospray ionization using multiple reaction monitoring (MRM). From the chlorpropamide plasma concentration vs time curves, the following pharmacoldnetic parameters were obtained: AUC(0-72h), AUC(inf) and C-max. Results: The limit of quantification was 0.1 mu g/mL for plasma chlorpropamide analysis. The geometric mean and respective 90% confidence interval (Cl) of Test/Reference percent ratios were 93.99% (87.11 %-101.41 %) for C-max, 92.45 % (85.96 %-99.44 %) for AUC(0-72h) and 90.30 % (83.35 %-97.82 %) for AUC(0-inf). Conclusion: Since the 90 % CI for AUC(0-72h), AUC(0-inf) and C-max ratios were within the 80-125 % interval proposed by the US FDA, it was concluded that chlorpropamide 250 mg tablet (test formulation) was bioequivalent to the reference 250 mg tablet for of both the rate and extent of absorption.57959159